Remote, Algorithm-Based Program Helps Patients Reach Target LDL-C Levels

An algorithm-based program that can be performed remotely is effective at achieving optimal low-density lipoprotein cholesterol (LDL-C) levels in the long term in patients with atherosclerotic cardiovascular disease (ASCVD), according to a study being presented at the American College of Cardiology 73rd Annual Scientific Session & Expo.

Significant gaps in lipid-lowering therapy persist and lead to patients failing to achieve guideline-defined LDL-C levels. The investigators of this analysis previously reported LDL-C reduction due to a disease management program. They implemented the remote, algorithmically driven lipid management program between 2018 and 2022. As part of the program, 7079 patients were enrolled in medication management, and 1215 opted for education only. Target LDL-C levels across 4 ASCVD risk groups were based on the 2018 American College of Cardiology/American Heart Association Guideline on the Management of Blood Cholesterol (LDL-C target for patients with ASCVD, <70 mg/dL; LDL-C target for other groups, <100 mg/dL).

The results showed that 75.7% and 83.1% of patients who completed the program achieved target LDL-C levels at 6 and 12 months, respectively, with similar effects observed across the 4 risk groups. The researchers noted that patients who dropped out of the program, but remained under usual care, had the lowest rates of achieving target LDL-C levels.

“A remote, algorithmically driven program, with minimal physician support, can successfully achieve target LDL-C levels and maintain [them] for at least 12 months across a diverse population at high risk of ASCVD. The attenuated effect on LDL-C in patients who prematurely discontinued the program highlights the need to improve patient engagement to maximize treatment plans,” the researchers concluded.